Symptomatic Bradycardia Associated with Beta-Blocker Therapy: Clinical Recognition, Risk Factors, Management and Pharmacovigilance-A Narrative Review

Abstract

Beta-adrenergic blockers are widely used in cardiovascular medicine because of their negative chronotropic, negative inotropic, and anti-ischemic effects. Although these agents provide substantial therapeutic benefits in conditions such as acute coronary syndrome, heart failure, hypertension, and cardiac arrhythmias, clinically significant bradycardia remains an important adverse drug reaction. The clinical significance of beta-blocker-associated bradycardia depends on the degree of heart-rate reduction, associated symptoms, hemodynamic status, underlying cardiac disease, concomitant medications, and potentially reversible causes. Metoprolol is a commonly prescribed cardio selective beta-blocker whose effects may be influenced by dose, drug interactions, organ function, and pharmacogenetic variability. This narrative review discusses the pharmacological basis of beta-blocker-associated bradycardia, clinical risk factors, differential diagnosis, medication-related contributors, drug interactions, diagnostic assessment, management principles, dechallenge, pharmacovigilance, and the role of clinical pharmacists. Evidence from pharmacovigilance databases and clinical studies indicates that beta-blocker-associated bradyarrhythmias can result in clinically important outcomes, including treatment discontinuation and, in selected patients, additional cardiac interventions. Current guidelines emphasize assessment of reversible causes and careful consideration of medication-related bradycardia. Pharmacogenetic evidence also indicates that CYP2D6 phenotype may influence metoprolol exposure and heart-rate response. Early recognition, structured medication reconciliation, ECG assessment, monitoring, and individualized treatment modification are therefore essential for safe beta-blocker therapy.